[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc announced the purchase of 5,357,044 ordinary shares of £0.01 each under the second tranche of its buyback programme. The company will hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 9,359,005 are held in treasury, leaving 8,942,994,643 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided link and on the company's investor website. The announcement notes this does not constitute an offer for securities.

Insights

Financial Analyst

TL;DR: The company executed a small tranche of its buyback, slightly reducing outstanding voting shares without material impact on capital structure.

The purchase of 5,357,044 shares under the second tranche is explicitly described and will be held as treasury shares, which reduces the number of shares with voting rights to 8,942,994,643. Given the scale of Haleon's registered share capital, this tranche represents a very small percentage of total shares and is unlikely to meaningfully affect EPS or control.

Corporate Governance Expert

TL;DR: The buyback follows announced programme procedures and updates the disclosure of voting rights and treasury holdings.

The filing complies with Market Abuse Regulation disclosure by providing a trade breakdown link and states intent to hold shares in treasury. The company clarifies the updated count of voting shares so shareholders can assess reporting thresholds under FCA rules. No governance or regulatory concerns are raised in the text itself.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒    Form 40-F ☐                 

EXHIBIT INDEX

Exhibit Number	Description
99.1	17 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

17 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 5,357,044 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	16 September 2025	16 September 2025	16 September 2025
Number of Shares purchased:	3,075,121	2,281,923	-
Highest price paid per Share (p):	350.3000	345.0000	-
Lowest price paid per Share (p):	340.9000	340.9000	-
Volume weighted average price paid per Share (p):	343.8060	342.7280	-

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 9,359,005 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,942,994,643 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/5932Z_1-2025-9-16.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 17, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary